Kura Oncology (KURA) Receivables - Accured (2020 - 2026)
Kura Oncology (KURA) reported Receivables - Accured of $4.3 million for Q1 2026, up 10.26% year-over-year from $3.9 million in Q1 2025, and up 13.16% on a QoQ basis from $3.8 million in Q4 2025.
Kura Oncology (KURA) has 7 years of Receivables - Accured data on file, last reported at $4.3 million in Q1 2026.
- Quarterly Receivables - Accured rose 10.26% year-over-year to $4.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.3 million (up 10.26% YoY) and the FY2025 annual result came in at $3.8 million, up 15.15% from the prior year.
- Receivables - Accured improved to $4.3 million in Q1 2026 per KURA's latest filing, from $3.8 million in the prior quarter.
- Across five years, Receivables - Accured topped out at $4.3 million in Q1 2026 and bottomed at $900000.0 in Q4 2022.
- The 5-year median for Receivables - Accured is $1.6 million (2022), against an average of $2.1 million.
- The widest annual swing landed in 2023, when Receivables - Accured sank 43.75%; it then surged 200.0% in 2024.
- Tracing KURA's Receivables - Accured over 5 years: stood at $900000.0 in 2022, then rose by 22.22% to $1.1 million in 2023, then surged by 200.0% to $3.3 million in 2024, then grew by 15.15% to $3.8 million in 2025, then increased by 13.16% to $4.3 million in 2026.
- Per Business Quant, the three latest KURA Receivables - Accured figures stand at $4.3 million (Q1 2026), $3.8 million (Q4 2025), and $3.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acc. Int. Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Kura Oncology | 801.92 Mn | 801.92 Mn | 18.00 Mn | 4.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.30 Mn |
| Mar 31, 2026 | 4.30 Mn |
| Dec 31, 2025 | 3.80 Mn |
| Dec 31, 2025 | 3.80 Mn |
| Sep 30, 2025 | 3.30 Mn |
| Sep 30, 2025 | 3.30 Mn |
| Jun 30, 2025 | 3.60 Mn |
| Jun 30, 2025 | 3.60 Mn |
| Mar 31, 2025 | 3.90 Mn |
| Mar 31, 2025 | 3.90 Mn |
| Dec 31, 2024 | 3.30 Mn |
| Dec 31, 2024 | 3.30 Mn |
| Sep 30, 2024 | 1.90 Mn |
| Sep 30, 2024 | 1.90 Mn |
| Jun 30, 2024 | 1.90 Mn |
| Jun 30, 2024 | 1.90 Mn |
| Mar 31, 2024 | 1.50 Mn |
| Mar 31, 2024 | 1.50 Mn |
| Dec 31, 2023 | 1.10 Mn |
| Dec 31, 2023 | 1.10 Mn |
| Sep 30, 2023 | 1.10 Mn |
| Sep 30, 2023 | 1.10 Mn |
| Jun 30, 2023 | 900,000.00 |
| Jun 30, 2023 | 900,000.00 |
| Mar 31, 2023 | 900,000.00 |
| Mar 31, 2023 | 900,000.00 |
| Dec 31, 2022 | 900,000.00 |
| Dec 31, 2022 | 900,000.00 |
| Sep 30, 2022 | 1.10 Mn |
| Sep 30, 2022 | 1.10 Mn |
| Jun 30, 2022 | 1.20 Mn |
| Jun 30, 2022 | 1.20 Mn |
| Mar 31, 2022 | 1.60 Mn |
| Mar 31, 2022 | 1.60 Mn |
| Dec 31, 2021 | 1.40 Mn |
| Dec 31, 2021 | 1.40 Mn |
| Dec 31, 2020 | 900,000.00 |
| Dec 31, 2020 | 900,000.00 |